Yi Larson

2020 - Turning Point Therapeutics

In 2020, Yi Larson earned a total compensation of $2.3M as Former Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, a 82% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$255,600
Option Awards$1,434,883
Salary$451,688
Other$114,716
Total$2,256,887

Larson received $1.4M in option awards, accounting for 64% of the total pay in 2020.

Larson also received $255.6K in non-equity incentive plan, $451.7K in salary and $114.7K in other compensation.

Rankings

In 2020, Yi Larson's compensation ranked 4,989th out of 13,090 executives tracked by ExecPay. In other words, Larson earned more than 61.9% of executives.

ClassificationRankingPercentile
All
4,989
out of 13,090
62nd
Division
Manufacturing
2,034
out of 5,618
64th
Major group
Chemicals And Allied Products
809
out of 2,251
64th
Industry group
Drugs
698
out of 1,951
64th
Industry
Pharmaceutical Preparations
525
out of 1,456
64th
Source: SEC filing on April 29, 2022.

Larson's colleagues

We found four more compensation records of executives who worked with Yi Larson at Turning Point Therapeutics in 2020.

2020

Athena Countouriotis

Turning Point Therapeutics

Chief Executive Officer

2020

Siegfried PHD

Turning Point Therapeutics

Chief Scientific Officer

2020

Annette North

Turning Point Therapeutics

General Counsel

2020

Mohammad Hirmand

Turning Point Therapeutics

Chief Medical Officer

News

In-depth

You may also like